171 related articles for article (PubMed ID: 37033868)
41. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
Reese MJ; Bowers GD; Humphreys JE; Gould EP; Ford SL; Webster LO; Polli JW
Xenobiotica; 2016; 46(5):445-56. PubMed ID: 26340566
[TBL] [Abstract][Full Text] [Related]
42. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
[TBL] [Abstract][Full Text] [Related]
43. Interactions Between Meropenem and Renal Drug Transporters.
Dong J; Liu Y; Li L; Ding Y; Qian J; Jiao Z
Curr Drug Metab; 2022 Aug; 23(5):423-431. PubMed ID: 35490314
[TBL] [Abstract][Full Text] [Related]
44. Characterization of Clofazimine as a Potential Substrate of Drug Transporter.
Jony MR; Cho YS; Long NP; Shin HJ; Shin JG
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0215821. PubMed ID: 35254089
[TBL] [Abstract][Full Text] [Related]
45. Sex, Organ, and Breed Differences in the mRNA Expression of Drug Transporters in the Liver and Kidney of Pigs.
Kojima M; Degawa M
Biol Pharm Bull; 2022; 45(4):508-516. PubMed ID: 35370276
[TBL] [Abstract][Full Text] [Related]
46. Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).
Zhu P; Ye Z; Guo D; Xiong Z; Huang S; Guo J; Zhang W; Polli JE; Zhou H; Li Q; Shu Y
Pharm Res; 2018 Oct; 35(12):243. PubMed ID: 30361780
[TBL] [Abstract][Full Text] [Related]
47. Interplay of the Organic Cation Transporters OCT1 and OCT2 with the Apically Localized Export Protein MATE1 for the Polarized Transport of Trospium.
Deutsch B; Neumeister C; Schwantes U; Fromm MF; König J
Mol Pharm; 2019 Feb; 16(2):510-517. PubMed ID: 30656943
[TBL] [Abstract][Full Text] [Related]
48. In vitro evaluation of potential transporter-mediated drug interactions of evogliptin.
Lee DY; Chae HW; Shim HJ
Biopharm Drug Dispos; 2017 Sep; 38(6):398-403. PubMed ID: 28503751
[TBL] [Abstract][Full Text] [Related]
49. Completing the Enalaprilat Excretion Pathway-Renal Handling by the Proximal Tubule.
Smeets NJL; Litjens CHC; van den Heuvel JJMW; van Hove H; van den Broek P; Russel FGM; Koenderink JB; de Wildt SN
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 33007874
[TBL] [Abstract][Full Text] [Related]
50. Assessment of the Drug Interaction Potential of Unconjugated and GalNAc
Shemesh CS; Yu RZ; Warren MS; Liu M; Jahic M; Nichols B; Post N; Lin S; Norris DA; Hurh E; Huang J; Watanabe T; Henry SP; Wang Y
Mol Ther Nucleic Acids; 2017 Dec; 9():34-47. PubMed ID: 29246313
[TBL] [Abstract][Full Text] [Related]
51. Machine learning models identify molecules active against the Ebola virus
Ekins S; Freundlich JS; Clark AM; Anantpadma M; Davey RA; Madrid P
F1000Res; 2015; 4():1091. PubMed ID: 26834994
[TBL] [Abstract][Full Text] [Related]
52. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
Kosloski MP; Bow DAJ; Kikuchi R; Wang H; Kim EJ; Marsh K; Mensa F; Kort J; Liu W
J Pharmacol Exp Ther; 2019 Aug; 370(2):278-287. PubMed ID: 31167814
[TBL] [Abstract][Full Text] [Related]
53. Studies on the interaction of five triazole fungicides with human renal transporters in cells.
Nie J; Zhou J; Shen Y; Lin R; Hu H; Zeng K; Bi H; Huang M; Yu L; Zeng S; Miao J
Toxicol In Vitro; 2023 Apr; 88():105555. PubMed ID: 36669674
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines.
Sayyed K; Camillerapp C; Le Vée M; Bruyère A; Nies AT; Abdel-Razzak Z; Fardel O
Toxicol In Vitro; 2019 Feb; 54():10-22. PubMed ID: 30189235
[TBL] [Abstract][Full Text] [Related]
55. Neonicotinoid pesticides poorly interact with human drug transporters.
Le Vée M; Bacle A; Bruyere A; Fardel O
J Biochem Mol Toxicol; 2019 Oct; 33(10):e22379. PubMed ID: 31364238
[TBL] [Abstract][Full Text] [Related]
56. Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase.
Tong Z; Gaudy A; Tatosian D; Ramirez-Valle F; Liu H; Chen J; Hoffmann M; Surapaneni S
Xenobiotica; 2021 Dec; 51(12):1416-1426. PubMed ID: 35000550
[TBL] [Abstract][Full Text] [Related]
57. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.
Müller F; König J; Hoier E; Mandery K; Fromm MF
Biochem Pharmacol; 2013 Sep; 86(6):808-15. PubMed ID: 23876341
[TBL] [Abstract][Full Text] [Related]
58. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.
Ma J; Beers B; Manohar R; Roe S; Colacino JM; Kong R
Pharmacol Res Perspect; 2021 Apr; 9(2):e00748. PubMed ID: 33749127
[TBL] [Abstract][Full Text] [Related]
59. Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance.
Shen H; Yang Z; Zhao W; Zhang Y; Rodrigues AD
Drug Metab Dispos; 2013 Dec; 41(12):2095-103. PubMed ID: 24026623
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
Vourvahis M; Byon W; Chang C; Le V; Diehl A; Graham D; Tripathy S; Raha N; Luo L; Mathialagan S; Dowty M; Rodrigues AD; Malhotra B
Clin Pharmacol Ther; 2022 Sep; 112(3):665-675. PubMed ID: 35344588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
